Clinical Trials Logo

Pituitary Neoplasms clinical trials

View clinical trials related to Pituitary Neoplasms.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06053437 Completed - Pituitary Adenoma Clinical Trials

Prognostic Indicators in Pituitary Adenoma Surgery: a Comprehensive Analysis of Surgical Outcomes and Complications.

Hyp'Op
Start date: February 1, 2023
Phase:
Study type: Observational

Predicting the outcome of pituitary surgery, particularly the risk of complications, is a critical determinant in selecting the appropriate treatment modality for patients. To date, only a limited number of risk factors have been identified for complications following pituitary surgery, including tumor size, younger age, and previous surgical intervention. Furthermore, existing studies have demonstrated that prolactin levels can serve as a surrogate marker for assessing pituitary function, specifically revealing associations between elevated prolactin levels and anterior pituitary insufficiencies. In a retrospective study on the "HYP'OP" cohort, the aim of the study is to identify predictive factors for both surgical outcomes and complications.

NCT ID: NCT05088252 Completed - Pituitary Neoplasms Clinical Trials

Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Nasal packing is required after endoscopic pituitary adenoma resection. The patient can only breathe through the mouth. The blood and secretion in the nasal cavity may be inhaled into the trachea after the operation. GH-secreting pituitary adenoma causes pharyngeal soft tissue and tongue hypertrophy. These conditions increase the risk of respiratory obstruction and hypoxemia during anesthesia recovery. Propofol total intravenous anesthesia has a rapid effect and a low incidence of nausea and vomiting. Patients anesthetized with desflurane recover quickly is conducive to early recovery of respiratory function and orientation. This study intends to compare the effects of desflurane and propofol on the quality of anesthesia recovery period in patients undergoing endonasal endoscopic pituitary adenoma resection and to provide clinical evidence for the use of desflurane in neurosurgical anesthesia.

NCT ID: NCT04840771 Completed - Pituitary Adenoma Clinical Trials

Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery

Start date: June 1, 2020
Phase:
Study type: Observational

This study evaluates the structural parameters, by spectral domain optical coherence tomography (OCT), retinal vessel density, using OCT angiography, and visual acuity in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

NCT ID: NCT04782596 Completed - Pituitary Adenoma Clinical Trials

Transnasal Endoscopic Pituitary Surgery - the Effect of Posterior Nasal Septum Resection on Nasal Functions

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The aim of the project is to compare the effect of different extent of resection of the posterior part of the septum on the postoperative nasal functions.

NCT ID: NCT04546386 Completed - Pituitary Adenoma Clinical Trials

Long-term Follow up for Retinal Vascular Changes After Endoscopic Endonasal Pituitary Surgery.

Start date: January 10, 2019
Phase:
Study type: Observational

This study investigates the retinal vascular features, using optical coherence tomography angiography, in patients during one year's follow up after the endoscopic endonasal surgery to remove an intra-suprasellar pituitary adenoma compressing the optic nerve.

NCT ID: NCT04425954 Completed - Pituitary Adenoma Clinical Trials

Evaluation of Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery

Start date: January 1, 2019
Phase:
Study type: Observational

This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

NCT ID: NCT04369703 Completed - Pituitary Tumor Clinical Trials

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

Start date: January 28, 2020
Phase:
Study type: Observational

1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.

NCT ID: NCT04284605 Completed - Pituitary Adenoma Clinical Trials

Effects Exercise Training in Patients With Pituitary Adenoma

Start date: May 15, 2020
Phase: N/A
Study type: Interventional

This study planned to investigate the effects of aerobic training combined with strengthening training and yoga on biochemical factors, physical performance and quality of life in people with pituitary adenoma. The hypotheses are; H1: Aerobic training combined with strengthening training is effective on biochemical factors in people with pituitary adenoma. H2: Aerobic training combined with strengthening training is effective on physical performance in people with pituitary adenoma. H3: Aerobic training combined with strengthening training is effective on quality of life in people with pituitary adenoma. H4: Yoga is effective on biochemical factors in people with pituitary adenoma. H5: Yoga is effective on physical performance in people with pituitary adenoma. H6: Yoga is effective on quality of life in people with pituitary adenoma. H7: Aerobic training combined with strengthening training and yoga is effective on biochemical factors, physical performance and quality of life in people with pituitary adenoma.

NCT ID: NCT04212793 Completed - Pituitary Adenoma Clinical Trials

Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

DEPARTURE
Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

There is a need for improved visualization of presence and extent of pituitary neuroendocrine tumor (PitNET) tissue during transsphenoidal surgery (TSS), especially in tumors invading the cavernous sinus (CS). Optical molecular imaging of PitNET associated biomarkers is a promising technique to accommodate this need. Vascular Endothelial Growth Factor (VEGF-A) is overexpressed in PitNET tissue compared to normal pituitary tissue and has proven to be a valid target for molecular imaging. Bevacizumab is an antibody that binds VEGF-A. By conjugating a fluorescent dye to this antibody, the fluorescent tracer molecule bevacizumab-800CW is created, which binds to VEGF-A. The investigators hypothesize that bevacizumab-800CW accumulates in PitNET tissue, enabling visualization using a molecular fluorescence endoscopy system. In this pilot intervention study the investigators will determine the feasibility of using microdoses (4.5, 10 and 25 mg) of bevacizumab-800CW to detect PitNET tissue intraoperatively.

NCT ID: NCT04076046 Completed - Pituitary Adenoma Clinical Trials

Multicentric Prospective Validation of the Zurich Pituitary Score

Start date: November 1, 2019
Phase:
Study type: Observational [Patient Registry]

Predictive analytics for GTR, EOR and RV are useful in surgical decision-making, particularly whenever there is no unequivocal indication for surgery. Several factors have been shown to have a role in predicting GTR. Among these, the Knosp classification has proven over the years to be a good predictor of GTR. The score is based on the lateral extension of the adenoma in relation the the intracranial bedding of the internal carotid artery. However, recent literature has demonstrated that the Knosp classification suffers from relatively poor interrater agreement. Moreover the classification was conceived in an era when endoscopic techniques were not available: nowadays endoscopic technique allows visualization and possibly also reaching portions of adenoma which at the time when the Knosp classification was introduced were simply not possible. Lastly, the efficacy of the Knosp's score in predicting also EOR and RV has never been tested. Recently a new score - the Zurich Pituitary Score (ZPS) has been proposed at the University Hospital of Zürich (USZ). The score has proved in the examined series to be more powerful than the Knosp classification in predicting GTR, EOR and RV. A good interrater agreement was also demonstrated. The score however, has been validated only in a monocentric setting with a limited number of patients. The aim of this study is to assess the (1) predictive ability of the ZPS for GTR, EOR, and RV, and (2) the inter-rater agreement of the ZPS in an external validation study.